The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

Picture a horse running across an open field, the wind blowing his mane, his hooves stamping into the grassy knoll, eyes on ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

Ryoncil ® was approved in December 2024 by the United States Food and Drug Administration (FDA) for steroid-refractory acute ...

Omeros Corporation today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings ? the Transplantation & Cellular Therapy Meetings of ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...

Cells in the body have to move around in order to do their jobs. During development, for instance, cells are distributed to ...

Researchers have discovered the mechanism that helps regulate the immune system’s response to helminth infection.

When a tumor develops, it creates a structure around itself called the tumor stroma, within which blood and lymphatic vessels ...

Scientists explore how the immune and nervous systems constantly communicate, influencing brain diseases, behavior, and ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...